Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1251P - Exploring quantitative biomarkers from different tumour volumes for radiomics in lung cancer

Date

17 Sep 2020

Session

E-Poster Display

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Sara Ramella

Citation

Annals of Oncology (2020) 31 (suppl_4): S744-S753. 10.1016/annonc/annonc263

Authors

S. Ramella1, R.M. D'angelillo2, M. Fiore1, C. Greco1, E. Ippolito1, N. D'Amico3, E. Cordelli4, R. Sicilia4, P. Soda4

Author affiliations

  • 1 Radiation Oncology, Policlinico Universitario Campus Bio-Medico, 00128 - Rome/IT
  • 2 Radiation Oncology, University of Rome Tor Vergata, 00133 - Rome/IT
  • 3 Biomedical Engineer, Centro Diagnostico Italiano, Milan/IT
  • 4 Computer Systems And Bioinformatics, Policlinico Universitario Campus Bio-Medico, 00128 - Rome/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1251P

Background

Recent advances in medical imaging technology allow the use of advanced image analysis methods by the extraction of quantitative features from medical images to characterize tumor biology in order to provide informations that may be useful to guide therapies and predict survival. In our previous experience, a radiomics signature mixing semantic and image-based features was able to predict the reduction of the target volume during chemoradiation in LA-NSCLC. The aim of this study is to investigate which 3D ROI contain more quantitative information that can be exploit for a radiomic approach in lung cancer.

Methods

We studied 122 LA- NSCLC treated with chemoradiation with or without adaptive approach, in order to investigate the predictive power of the radiomic features on tumor shrinkage. Gross Tumour Volume (GTV), Clinical Tumour Volume (CTV) and Planned Tumour Volume (PTV) were manually delineated by expert radiation oncologists, providing three 3D ROIs. For each ROI we computed 105 quantitative biomarkers using the opensource software platform PyRadiomics. The features belong to the following subgroups: Shape based measures, First Order Statistics, Gray Level Cooccurence Matrix, Gray Level Run Length Matrix, Gray Level Size Zone Matrix, Neighbouring Gray Tone Difference Matrix and Gray Level Dependence Matrix. For feature selection and classification ee use leave-one-patient out approach and, for each run, we proceeded ranked all the features using the recursive feature elimination (RFE) method and then we trained an AdaBoost meta-classifier. Such a training-testing procedure was repeated adding every time a new feature according to the RFE output.

Results

The largest accuracy (80.3%) is obtained using 16 features computed from CTV ROIs. From the 16 features which gave the best result 5 belonged to the shape feature class, 5 to the First oder Statistics, 2 to the class GLDM, 2 to the NGTDM class, and one feature belonged to the classes GLCM and GLSZM, respectively.

Conclusions

These preliminary results suggest that there may also be useful information in healthy tissue bordering on neoplastic disease macroscopically evident in imaging. Further work is needed to substantiate the proposed hypothesis.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.